YESINTEK™, a monoclonal antibody, is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.

It has approved YESINTEK, a monoclonal antibody, which is approved for the treatment of Crohn’s disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis. The company spokesperson ...

Biocon Biologics (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

Optimism for Biocon is fuelled by the green light for its Bengaluru biologics unit, paired with the USFDA approval for the launch of its Stelara biosimilar for autoimmune disorders, ...

YESINTEK is used for the treatment of adults and children with plaque psoriasis, and adults with psoriatic arthritis or Crohn’s disease. The company has acquired a 74% stake in Navi Mumbai IIA ...

The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a commercial launch date expected for early 2025, according to a press release from Biocon ...

Medscape Medical News, December 03, 2024 Alert FDA Approves Ustekinumab Biosimilar Yesintek This is the sixth ustekinumab biosimilar approval in the United States, with the drug set to launch in 2025.